about
Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethalityTargeting the insulin growth factor receptor 1Mitophagy: In sickness and in healthChemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agentsAdipocytes: impact on tumor growth and potential sites for therapeutic interventionPleiotropic role of HSF1 in neoplastic transformationNovel Therapy to Treat Corneal Epithelial Defects: A Hypothesis with Growth HormoneThe Warburg effect revisited--lesson from the Sertoli cellEpitope-specific mechanisms of IGF1R inhibition by ganitumabInsulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancerThe rebel angel: mutant p53 as the driving oncogene in breast cancer.Simulation predicts IGFBP2-HIF1α interaction drives glioblastoma growthThe insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.Impaired glucose metabolism among those with and without diagnosed diabetes and mortality: a cohort study using Health Survey for England data.RFP-mediated ubiquitination of PTEN modulates its effect on AKT activationA crayfish insulin-like-binding protein: another piece in the androgenic gland insulin-like hormone puzzle is revealedIndirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activitySignificantly increased risk of cancer in diabetes mellitus patients: A meta-analysis of epidemiological evidence in Asians and non-Asians.Latest insights into the risk of cancer in diabetesThe Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity.Identification of fatty acid binding protein 4 as an adipokine that regulates insulin secretion during obesity.Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model.The risk of colonic adenomas and colonic cancer in obesityDose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations.IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.The role of adiponectin in cancer: a review of current evidence.Obesity and cancer risk: evidence, mechanisms, and recommendationsCardiorespiratory fitness, body mass index, and cancer mortality: a cohort study of Japanese menGlargine safety, diabetes and cancer.Aflatoxin B1 up-regulates insulin receptor substrate 2 and stimulates hepatoma cell migrationTeprotumumab for Thyroid-Associated Ophthalmopathy.IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review).Serum glucose and fructosamine in relation to risk of cancerReduced signaling of PI3K-Akt and RAS-MAPK pathways is the key target for weight-loss-induced cancer prevention by dietary calorie restriction and/or physical activity.Diabetes mellitus and ovarian cancer: more complex than just increasing riskSuccinate dehydrogenase-deficient gastrointestinal stromal tumors.Physical inactivity and low fitness deserve more attention to alter cancer risk and prognosis.Mechanisms of obesity-induced gastrointestinal neoplasiaPolymorphisms in the insulin-like growth factor axis are associated with gastrointestinal cancer.
P2860
Q24311618-A120290D-3981-487E-A859-1928E675D251Q24633750-08568CE2-C948-487C-9720-0E122B1F9370Q26745675-7F10BEA2-A67E-4C98-BB70-9AE506B17763Q26772302-FA6BFB7D-506B-412B-86AD-81C41FD3B018Q26830077-D8D19126-6256-4974-A4CC-A326BE315F0EQ27010679-0E4A630E-8617-4452-8005-F0385DC428D9Q27021208-BE2D5AC8-9CC2-43B7-8925-88AC9A041DE9Q27025749-8B6D9B2C-F9F0-4910-8AA7-1AA2E0C70DCCQ27317385-B31BA7B6-BD9D-4631-9CA8-F734B541D6DEQ27322873-9BD73906-F494-4679-B8F8-544A0ABD10A3Q27686765-ED1174F5-95D8-4A11-8753-F9FFD361957DQ28546518-3970BEE2-0B17-4FA2-8C27-7181E773B221Q30244095-9E5EC6C4-64E5-47B6-92A7-9BC46CBCCAF2Q30912182-67671288-18C8-4E25-8E23-3F55A34FCC5EQ32884571-0F876AB4-A1F3-4187-A129-F22139D55A9BQ33356013-0B946E2C-6F10-4CC4-B58F-A677051E4D6CQ33572235-17E01A0F-972C-444C-85D0-3AFFDD4C0F18Q33585663-D28D6EAF-C1FB-4376-A1DB-B842251CE6C1Q33588852-9A69BBEF-BFC2-4A15-989E-485CBD6819F4Q33602919-59E46626-2DC6-4526-8248-D94B04E4AAD3Q33765653-23275329-BFBA-40B3-961E-111EE7D6E92EQ33777669-D4FBA48F-9016-4DD9-9873-B20BC087337AQ34157499-F7A57077-3B4B-4146-AB0D-39B90FB1A6E3Q34159910-AD8F05F1-7353-4241-A3AE-A817DD4774B5Q34159954-372B74C3-4CB9-4895-871E-0A81A75F0EA6Q34255487-CCC79207-B644-4FE7-8CE5-7DFD314C14D6Q34271986-4E24CFA2-4FBB-443B-ACEA-B6EFA29490A4Q34305020-7BCF2554-BCA4-4025-B027-FEF30964A42BQ34308938-477A57A7-0005-4999-843C-69033FF909D2Q34326924-BC3FB96D-494C-40C5-A708-A875CACB681EQ34462465-6A69C999-20B6-4D3F-90DF-C7D37134A02BQ34556184-4B30A340-4A47-41FE-9582-C045DF7346D1Q34556695-DDC78BF0-EE42-474F-8208-020CE1A382E1Q34571468-17E33583-D4B9-42B1-889D-3D95D0152194Q34614287-93E64D0B-2EEC-42AB-9A4E-2D1978137DFDQ34615282-082A90F8-0CE6-4867-9EB0-CD92BA116493Q34668378-C144EE44-EB2C-4A95-9654-CAA733A44563Q35044358-CD5B4148-734C-458D-9CD1-4580A2AD9487Q35062195-CCB79303-129F-4C42-A38B-0906BFF2BD85Q35114419-D555ACFD-1C15-4D5D-8B99-864BF8AED691
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Minireview: IGF, Insulin, and Cancer.
@en
Minireview: IGF, Insulin, and Cancer.
@nl
type
label
Minireview: IGF, Insulin, and Cancer.
@en
Minireview: IGF, Insulin, and Cancer.
@nl
prefLabel
Minireview: IGF, Insulin, and Cancer.
@en
Minireview: IGF, Insulin, and Cancer.
@nl
P356
P1433
P1476
Minireview: IGF, Insulin, and Cancer.
@en
P2093
Emily J Gallagher
P304
P356
10.1210/EN.2011-0231
P407
P577
2011-05-03T00:00:00Z